R M Hirschfeld1. 1. Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch at Galveston, 1.302 Rebecca Sealy, 301 University Blvd, Galveston, TX 77555-0188, USA. rohirsch@utmb.edu
Abstract
BACKGROUND: Depression, which only a few decades ago was considered to be a short-term illness requiring short-term treatment, is now recognised as a recurrent, sometimes chronic, long-term illness. AIMS: To highlight the clinical importance of long-term antidepressant therapy in the treatment of depression. METHOD: The current literature was reviewed to examine the relationship between duration of antidepressant therapy and efficacy. RESULTS: Approximately one-third to a half of patients successfully stabilised in acute-phase treatment will relapse if medication is not sustained throughout the continuation period. Only 10-15% will relapse if medication is continued. For maintenance-phase therapy, approximately 60% of patients at risk will experience a recurrent episode of depression within 1 year if untreated, whereas those who continue in treatment will have a recurrence rate of between 10% and 30%. CONCLUSIONS: Risk of relapse and recurrence of depression can be significantly reduced if adequate continuation and maintenance therapy durations are achieved.
BACKGROUND:Depression, which only a few decades ago was considered to be a short-term illness requiring short-term treatment, is now recognised as a recurrent, sometimes chronic, long-term illness. AIMS: To highlight the clinical importance of long-term antidepressant therapy in the treatment of depression. METHOD: The current literature was reviewed to examine the relationship between duration of antidepressant therapy and efficacy. RESULTS: Approximately one-third to a half of patients successfully stabilised in acute-phase treatment will relapse if medication is not sustained throughout the continuation period. Only 10-15% will relapse if medication is continued. For maintenance-phase therapy, approximately 60% of patients at risk will experience a recurrent episode of depression within 1 year if untreated, whereas those who continue in treatment will have a recurrence rate of between 10% and 30%. CONCLUSIONS: Risk of relapse and recurrence of depression can be significantly reduced if adequate continuation and maintenance therapy durations are achieved.
Authors: Adam Greenlee; Jordan F Karp; Mary Amanda Dew; Patricia Houck; Carmen Andreescu; Charles F Reynolds Journal: Depress Anxiety Date: 2010-05 Impact factor: 6.505
Authors: Welmoed E E Meijer; E R Heerdink; Hubert G M Leufkens; Ron M C Herings; Antoine C G Egberts; Willem A Nolen Journal: Eur J Clin Pharmacol Date: 2004-02-19 Impact factor: 2.953
Authors: Katelyn R Keyloun; Ryan N Hansen; Zsolt Hepp; Patrick Gillard; Michael E Thase; Emily Beth Devine Journal: CNS Drugs Date: 2017-05 Impact factor: 5.749